首页> 外文OA文献 >Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study

【2h】

Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study

机译：曲妥珠单抗Emtansine联合或不联合帕妥珠单抗与曲妥珠单抗加紫杉烷治疗人表皮生长因子受体2阳性晚期乳腺癌：MARIANNE III期研究的主要结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Perez, Edith A.; Barrios, Carlos; Eiermann, Wolfgang; Toi, Masakazu; Im, Young-Hyuck; Conte, Pierfranco; Martin, Miguel; Pienkowski, Tadeusz; Pivot, Xavier; Burris, Howard; Petersen, Jennifer A.; Stanze, Sven; Strasak, Alexander; Patre, Monika; Ellis, Paul;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017) [J] . Perez Journal of Clinical Oncology . 2017,第20期

机译：曲妥珠单抗与Pertuzumab与retsuzumab和紫罗兰人为人体表皮生长因子受体2阳性，晚期乳腺癌的紫罗兰毒素：III期玛丽安学习的主要结果（Vol 35，PG 141,2017）
2. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2 Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017) [J] . Burris Howard A. Journal of Clinical Oncology . 2019,第4期

机译：具有或不含Pertuzumab的曲妥珠单抗与曲妥珠单抗加紫罗兰人对人体表皮生长因子受体2阳性，晚期乳腺癌：III期Marianne研究的主要结果（Vol 35，PG 141,2017）
3. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE [J] . Perez Edith A., Barrios Carlos, Eiermann Wolfgang, Cancer: A Journal of the American Cancer Society . 2019,第22期

机译：Trastuzumab emtansine有或没有Pertuzumab与脂肪株与人表皮生长因子受体2阳性晚期乳腺癌的脂肪株：来自Marianne的最终结果
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study [O] . Edith A. Perez, Carlos Barrios, Wolfgang Eiermann, -1

机译：曲妥珠单抗Emtansine与或不与曲妥珠单抗相比曲妥珠单抗加紫杉烷对人类表皮生长因子受体2阳性晚期乳腺癌的研究：III期MARIANNE研究的主要结果
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study

著录项

引文网络

相似文献

相关主题

期刊订阅